GlassScriptPhysician profile
George Nicholas Stokes
NPI 1003824509
$13,253.51
in general payments reported to CMS, 2019-2025
57 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,503 · 2020: $1,969 · 2021: $2,122 · 2022: $1,987 · 2023: $1,425 · 2024: $1,540 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,517 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,516.91 |
| Education | $156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,131.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,823.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,442.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $861.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $599.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $567.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.18 | 2019-2025 | Xifaxan |
| Abbvie INC. | $503.97 | 2021-2024 | Vraylar, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $403.11 | 2022-2025 | |
| Mylan Specialty L.P. | $362.18 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.57 | 2019-2023 | Stiolto Respimat |
| Sunovion Pharmaceuticals INC. | $300.46 | 2019-2022 | |
| Inspire Medical Systems, INC. | $294.97 | 2022-2025 | Inspire |
| Corcept Therapeutics | $283.01 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $204.66 | 2019-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.